MMP9 and intracranial hemorrhage: A dose–response relationship was observed between the incidence of symptomatic intracranial hemorrhage and MMP9/TIMP1 ratio quartiles (4.9% of SICH in the first quartile; 6.1% in the second quartile, 7.4% in the third quartile, 14.6% in the fourth quartile, p = 0.025) and MMP9/TIMP2 ratio quartiles (4.9% of SICH in the first quartile; 3.7% in the second quartile, 8.5% in the third quartile, 15.9% in the fourth quartile, p = 0.006).